GlassScriptPhysician profile
Julia Parsons
NPI 1114474319
$3,128.45
in general payments reported to CMS, 2019-2025
23 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $41.61 · 2023: $463 · 2024: $571 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.46 |
| Education | $463.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $610.70 | 2024-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $445.47 | 2021-2025 | |
| Pfizer INC. | $357.40 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $251.70 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $246.27 | 2025 | |
| Genzyme Corporation | $214.43 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $180.50 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $105.62 | 2022-2025 | Ebglyss, Taltz |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Galderma Laboratories, L.P. | $91.94 | 2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $80.75 | 2023-2024 | Dupixent |
| Arcutis Biotherapeutics, INC. | $61.09 | 2023-2025 | Zoryve |
| Ucb, INC. | $60.30 | 2024-2025 | Bimzelx |
| Incyte Corporation | $47.42 | 2023-2024 | Opzelura |
| Organon LLC | $46.37 | 2025 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.97 | 2021-2025 | Otezla |
| Dermavant Sciences, INC. | $41.08 | 2023 | Vtama |
| Journey Medical Corporation | $39.49 | 2025 | |
| Botanix Sb INC | $38.37 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.02 | 2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $14.73 | 2024 | Ycanth |
| Leo Pharma INC. | $14.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.